Next-Generation Sequencing (NGS) significantly changed cancer management, allowing the identification of different oncogenic drivers and the subsequent approval of many targeted agents. An overview of the Belgian reimbursement situation and drug access in this setting was given during the molecular tests in oncology session of the Belgian Society of Medical Oncology (BSMO) annual meeting. First, Prof. Brigitte Maes (Jessa Hospital, Hasselt) walked us through the current NGS situation in
Belgium with a discussion of the achievements and challenges of the BALLETT study. Subsequently, Dr. Kevin Punie (Leuven University Hospital, Leuven) discussed the current strategy, tasks and challenges of the molecular tumour board (MTB). Finally, Pr. Lore Decoster (University Hospital Brussel), Dr. Wim Demey (Klina General Hospital, Brasschaat) and Dr. Joëlle Collignon (CHU de Liège, Liège) addressed the reimbursements of drugs in lung, gastro-oesophageal, biliary and pancreatic cancer.